191 related articles for article (PubMed ID: 16555681)
1. Drug-induced effects on cholesterol catabolism and bile acids.
Gylling H; Miettinen TA
Curr Opin Investig Drugs; 2006 Mar; 7(3):214-8. PubMed ID: 16555681
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.
Kobayashi M; Ikegami H; Fujisawa T; Nojima K; Kawabata Y; Noso S; Babaya N; Itoi-Babaya M; Yamaji K; Hiromine Y; Shibata M; Ogihara T
Diabetes; 2007 Jan; 56(1):239-47. PubMed ID: 17192488
[TBL] [Abstract][Full Text] [Related]
3. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
4. Beyond statins. New drugs can work with, or in place of, cholesterol-lowering statins.
Harv Heart Lett; 2003 Feb; 13(6):3. PubMed ID: 12604459
[No Abstract] [Full Text] [Related]
5. New therapies on the horizon.
Brown WV
Am J Manag Care; 2001 May; 7(5 Suppl):S148-51. PubMed ID: 11383377
[TBL] [Abstract][Full Text] [Related]
6. Update on patented cholesterol absorption inhibitors.
Chhabria MT; Mahajan BM
Expert Opin Ther Pat; 2009 Aug; 19(8):1083-107. PubMed ID: 19552506
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
[TBL] [Abstract][Full Text] [Related]
8. Colesevelam hydrochloride in the management of dyslipidemia.
Armani A; Toth PP
Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
[TBL] [Abstract][Full Text] [Related]
9. [Cholesterol metabolism modulators in future drug therapy for atherosclerosis].
Morozova S; Suc-Royer I; Auwerx J
Med Sci (Paris); 2005 Dec; 21 Spec No():53-8. PubMed ID: 16598906
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe decreases serum oxidized cholesterol without impairing bile acid synthesis in Japanese hypercholesterolemic patients.
Hirayama S; Nakagawa S; Soda S; Kamimura Y; Nishioka E; Ueno T; Fukushima Y; Higuchi K; Inoue M; Seino U; Ohmura H; Yamato S; Miida T
Atherosclerosis; 2013 Sep; 230(1):48-51. PubMed ID: 23958251
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond.
Couture P; Lamarche B
Curr Opin Lipidol; 2013 Jun; 24(3):227-32. PubMed ID: 23571732
[TBL] [Abstract][Full Text] [Related]
12. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment.
Berthold HK; Laaksonen R; Lehtimäki T; Gylling H; Krone W; Gouni-Berthold I
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):262-7. PubMed ID: 18072016
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe: cholesterol lowering and beyond.
Bays HE; Neff D; Tomassini JE; Tershakovec AM
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
[TBL] [Abstract][Full Text] [Related]
14. Role of bile acid sequestrants in the treatment of type 2 diabetes.
Handelsman Y
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S244-50. PubMed ID: 21525463
[No Abstract] [Full Text] [Related]
15. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.
Corsini A; Windler E; Farnier M
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):1-9. PubMed ID: 19237992
[TBL] [Abstract][Full Text] [Related]
16. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation.
Brinton EA
Diabetes Obes Metab; 2008 Nov; 10(11):1004-11. PubMed ID: 18494807
[TBL] [Abstract][Full Text] [Related]
17. Human cholesterol metabolism and therapeutic molecules.
Charlton-Menys V; Durrington PN
Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
[TBL] [Abstract][Full Text] [Related]
18. Promising therapies for cholesterol reduction.
Brown WV
Manag Care; 2002 Sep; 11(9 Suppl):10-4. PubMed ID: 12369337
[No Abstract] [Full Text] [Related]
19. Safety considerations with gastrointestinally active lipid-lowering drugs.
Jacobson TA; Armani A; McKenney JM; Guyton JR
Am J Cardiol; 2007 Mar; 99(6A):47C-55C. PubMed ID: 17368279
[TBL] [Abstract][Full Text] [Related]
20. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
